Phase II Trial of Carboplatin +/- Tocilizumab for Metastatic Triple Negative and ER-low Breast Cancers
Status:
Not yet recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
This is a randomized Phase II study of carboplatin monotherapy vs. carboplatin combined with
tocilizumab in in Black and non-Black patients with metastatic triple negative or ER low
breast cancer.